Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1987 2
1989 1
1990 4
1991 5
1992 5
1993 5
1994 3
1995 10
1996 2
1997 5
1998 9
1999 7
2000 9
2001 10
2002 8
2003 12
2004 3
2005 6
2006 14
2007 7
2008 18
2009 12
2010 20
2011 12
2012 17
2013 13
2014 18
2015 8
2016 12
2017 15
2018 14
2019 8
2020 7
2021 4
2022 3
2023 6
2024 3
2025 9
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296 results

Results by year

Filters applied: . Clear all
Page 1
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. Grundy SM, et al. Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10. Circulation. 2019. PMID: 30586774 Free PMC article.
Assess adherence and percentage response to LDL-C-lowering medications and lifestyle changes with repeat lipid measurement 4 to 12 weeks after statin initiation or dose adjustment, repeated every 3 to 12 months as needed. Define responses to lifestyle and …
Assess adherence and percentage response to LDL-C-lowering medications and lifestyle changes with repeat lipid measurement 4 to 12 we …
The Role of Lipids and Lipoproteins in Atherosclerosis.
Linton MF, Yancey PG, Davies SS, Jerome WG, Linton EF, Song WL, Doran AC, Vickers KC. Linton MF, et al. 2019 Jan 3. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2019 Jan 3. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 26844337 Free Books & Documents. Review.
Population studies have demonstrated that elevated levels of LDL cholesterol and apolipoprotein B (apoB) 100, the main structural protein of LDL, are directly associated with risk for atherosclerotic cardiovascular events (ASCVE). ...Lowering LDL-cholesterol with …
Population studies have demonstrated that elevated levels of LDL cholesterol and apolipoprotein B (apoB) 100, the main structu …
Efficacy and Safety of Bempedoic Acid in Japanese Patients With Hypercholesterolemia　- A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (the CLEAR-J Trial).
Yamashita S, Kiyosue A, Fujita H, Yokota D, Nakamura Y, Yasuda S. Yamashita S, et al. Circ J. 2025 Jul 25;89(8):1256-1265. doi: 10.1253/circj.CJ-25-0089. Epub 2025 Apr 28. Circ J. 2025. PMID: 40159243 Free article. Clinical Trial.
BACKGROUND: Statins can effectively reduce low-density lipoprotein cholesterol (LDL-C), but additional options are needed for inadequate responses to statins or statin intolerance. ...CONCLUSIONS: This study confirmed the safety and efficacy of bempedo …
BACKGROUND: Statins can effectively reduce low-density lipoprotein cholesterol (LDL-C), but additional options are needed for inadequ …
Hypercholesterolemia of Cholestasis.
Charlat M, Poltiyelova E, Silverman J, Lit A, Frishman WH, Lebovics E. Charlat M, et al. Cardiol Rev. 2025 Jul 11. doi: 10.1097/CRD.0000000000000994. Online ahead of print. Cardiol Rev. 2025. PMID: 40643256
Cardiovascular risk stratification of patients with PBC is most accurately achieved by direct measurement of apolipoprotein B, the protein component of pro-atherosclerotic lipoproteins involved in cholesterol transport. First and second line therapies for the treatm …
Cardiovascular risk stratification of patients with PBC is most accurately achieved by direct measurement of apolipoprotein B, …
Use of Apolipoprotein B in the Era of Precision Medicine: Time for a Paradigm Change?
Cole J, Zubirán R, Wolska A, Jialal I, Remaley AT. Cole J, et al. J Clin Med. 2023 Sep 3;12(17):5737. doi: 10.3390/jcm12175737. J Clin Med. 2023. PMID: 37685804 Free PMC article. Review.
Ongoing management of these patients relies on the accurate assessment of their response to any prescribed therapy, and their residual risk, in order to optimize treatment. Recent international guidelines and position statements concur that the plasma concentration of a …
Ongoing management of these patients relies on the accurate assessment of their response to any prescribed therapy, and their residua …
Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial.
Ray KK, Oru E, Rosenson RS, Jones J, Ma X, Walgren J, Haupt A, Verma S, Gaudet D, Nicholls SJ, Ruotolo G. Ray KK, et al. Lancet. 2025 May 3;405(10489):1594-1607. doi: 10.1016/S0140-6736(25)00507-0. Epub 2025 Mar 31. Lancet. 2025. PMID: 40179932 Free article. Clinical Trial.
Using an interactive web-response system, patients were randomly assigned (1:2:2:2) to receive either solbinsiran 100 mg, solbinsiran 400 mg, solbinsiran 800 mg, or placebo, by subcutaneous injection on days 0 and 90. ...The primary outcome was percent change in apolipo …
Using an interactive web-response system, patients were randomly assigned (1:2:2:2) to receive either solbinsiran 100 mg, solbinsiran …
Regulation of PCSK9 by nutraceuticals.
Momtazi AA, Banach M, Pirro M, Katsiki N, Sahebkar A. Momtazi AA, et al. Pharmacol Res. 2017 Jun;120:157-169. doi: 10.1016/j.phrs.2017.03.023. Epub 2017 Mar 29. Pharmacol Res. 2017. PMID: 28363723 Review.
PCSK9 inhibition is also an effective adjunct to statin therapy; however, the cost-effectiveness of currently available PCSK9 inhibitors is under question. ...Mechanistically, those nutraceuticals that inhibit PCSK9 through a SREBP (sterol-responsive element …
PCSK9 inhibition is also an effective adjunct to statin therapy; however, the cost-effectiveness of currently available PCSK9 inhi …
Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.
Geba GP, Mohammadi KA, Damask A, Paulding C, Lotta LA, Hindy G, Pordy R, Manvelian G, Shapiro MD, Bittner VA, Bhatt DL, Szarek M, Schwartz GG, Steg PG, Fazio S. Geba GP, et al. J Am Heart Assoc. 2025 Sep 2;14(17):e041190. doi: 10.1161/JAHA.124.041190. Epub 2025 Aug 22. J Am Heart Assoc. 2025. PMID: 40847481 Free PMC article. Clinical Trial.
Patients had T3HLP if the ratio, validated using the UK Biobank database, of non-high-density lipoprotein cholesterol/apolipoprotein B was >2.6. Genetic variation affecting low-density lipoprotein cholesterol levels (HeFH) and APOE genotypes (T3HLP) was assessed …
Patients had T3HLP if the ratio, validated using the UK Biobank database, of non-high-density lipoprotein cholesterol/apolipoprotein …
Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes.
Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF, Barrett PH. Pang J, et al. Diabetes Obes Metab. 2016 Apr;18(4):384-91. doi: 10.1111/dom.12622. Epub 2016 Jan 28. Diabetes Obes Metab. 2016. PMID: 26679079 Free article. Clinical Trial.
AIM: To investigate the effects of extended-release (ER) niacin on apolipoprotein B-48 (apoB-48) kinetics in statin-treated patients with type 2 diabetes (T2DM). ...Area-under-the-curve (AUC) and incremental AUC (iAUC) for plasma triglyceride and apoB-48 were …
AIM: To investigate the effects of extended-release (ER) niacin on apolipoprotein B-48 (apoB-48) kinetics in statin-tre …
Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men.
Chan DC, Watts GF, Wang J, Hegele RA, van Bockxmeer FM, Barrett PH. Chan DC, et al. Clin Endocrinol (Oxf). 2008 Jul;69(1):45-51. doi: 10.1111/j.1365-2265.2007.03144.x. Epub 2008 Jul 1. Clin Endocrinol (Oxf). 2008. PMID: 18031309 Clinical Trial.
We examined the association of common genetic polymorphisms in NPC1L1 on apolipoprotein (apo) B-100 metabolism and the response to statin treatment in 37 men with central obesity. RESEARCH METHODS AND PROCEDURE: Very-low density lipoprotein (VLDL) and low-density li …
We examined the association of common genetic polymorphisms in NPC1L1 on apolipoprotein (apo) B-100 metabolism and the response to …
296 results